Hepatocellular carcinoma
Conditions
Interventions
Case series:Jiedu Granule
Sponsors
Changhai Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Male or female aged older than 18 years; 2. Histologically diagnosed HCC, OR clinically diagnosed HCC; 3. Documented progression with or intolerance to first-line sorafenib monotherapy and sorafenib-based combination as first-line therapy for advanced HCC; 4. For patients who receive first-line sorafenib monotherapy or sorafenib-based combination, patients must have received at least 14 days of sorafenib treatment with the lowest dosage of 400 mg per day; 5. Stage is C according to the BCLC staging classification; 6. ECOG performance status 0 or 1.
Exclusion criteria
Exclusion criteria: 1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment; 2. Local treatment including radiotherapy (except palliative radiotherapy), percutaneous ethanol injection, radiofrequency ablation, transarterial embolization, or cryotherapy administered within 4 weeks prior to enrollment; 3. Had a solid organ transplant; 4. Presence of brain or leptomeningeal metastases; 5. Has had esophageal or gastric variceal bleeding within the last 6 months; 6. the researchers consider those who were not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival;Objective Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival;Disease Control Rate; | — |
Countries
China
Contacts
Public ContactXiaofeng Zhai
Changhai Hospital
Outcome results
None listed